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Abstract
Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder charac-
terized by multiple hormonal imbalances, reflecting on the clinical presentation. 
Among them, the insulin resistance (IR), defined as a metabolic state characterized 
by a decrease in cellular ability to respond to insulin signaling, is a key feature of 
PCOS independently of obesity. Thus, IR occurs in more than 70% of obese PCOS 
women and in 30–50% of lean ones. Compensatory high insulin levels are both a 
symptom and an underlying physiopathological driver of PCOS. Insulin appears 
to disrupt all components of the hypothalamic-pituitary-ovarian axis, and ovarian 
tissue IR results in impaired metabolic signaling but intact mitogenic and steroido-
genic activity, favoring hyperandrogenemia. The latter is the main culprit of the 
clinical picture in PCOS. Testing for IR can be helpful to rule out other conditions 
that are commonly misdiagnosed as PCOS and to recommend an appropriate treat-
ment for the different PCOS phenotypes.
Keywords: polycystic ovary syndrome, insulin resistance, obesity, adipose tissue, 
adipocytokines
1. Introduction
Polycystic ovary syndrome (PCOS) is emerging as one of the most common 
endocrine disorders, affecting about 5–14% of the women of reproductive age and 
a leading cause of infertility [1–3]. In recent decades, there has been a wealth of 
evidence that the disease is a typical example of a female sex specific metabolic syn-
drome (MetS) due to IR, with obesity having an additional aggravating effect [4–6]. 
The interest in PCOS, from its first description in 1935 by Stein and Leventhal as 
a combination of bilaterally enlarged polycystic ovaries with manifest hirsutism, 
obesity, amenorrhea/oligomenorrhea, and infertility in a group of women [7], is an 
ever increasing one, becoming interdisciplinary, as affected girls and young women 
are at increased risk of cardiovascular disease (CVD) compared to age-matched 
healthy women [8–10]. This opinion is based mainly on the metabolic disorders 
established in PCOS (Table 1).
PCOS is a complex disorder that results from the interaction of diverse genetic 
and environmental factors. Heritable factors include polycystic ovarian morphol-
ogy due to functional ovarian steroidogenic defects, hyperandrogenemia, IR, and 
insulin secretory defects. Acquired obesity is a major postnatal unfavorable factor 
[11] (Figure 1).
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The major atherogenic risk factor is IR, since excluding all other pathological 
abnormalities, weight included, the hyperinsulinemic women with PCOS have a 
5-fold higher incidence of CVD risk factors than the normoinsulinaemic ones. But 
the latter, in turn, remain at a significantly higher CVD risk than their age-and BMI-
matched healthy controls [12]. This fact supports the main impact of the disease 
itself. The role of hyperandrogenemia as an independent determinant of CVD risk 
in PCOS is controversial—there are studies supporting [13] and rejecting [14] the 
direct link; moreover, elevated androgen levels are interpreted by most authors as 
being secondary to an underlying IR [15–17].
Not only does the presence of hyperandrogenemia and IR/compensatory hyper-
insulinemia in PCOS elucidate such important pathogenetic mechanisms of the 
disease, but some clinical observations show that, in fact, the late metabolic com-
plications are more deleterious than the reproductive dysfunction itself. Moreover, 
recent data from a long-term prospective study indicate that hyperinsulinemia 
and IR tend to deepen spontaneously in PCOS women, even without worsening 
of the hyperandrogenism [18]. PCOS is a markedly heterogeneous disease that is 
Figure 1. 
Mechanisms by which obesity may determine the obese PCOS phenotype (adаpted according to [11]).
Overweight/obesity (android type)
Insulin resistance/hyperinsulinemia
Impaired fasting glucose (IFG)/impaired glucose tolerance (IGT)/
Diabetes mellitus (DM) type 2
Gestational diabetes mellitus
Dyslipidemia (↓HDL-cholesterol; ↑ triglycerides)
Arterial hypertension/Arterial hypertension during pregnancy
Hypercoagulation
Hyperuricemia
Table 1. 
Metabolic disorders in PCOS.
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why the results of numerous studies on CVD risk assessment in the PCOS women 
are controversial. This is due to some differences in research trial designs and the 
characteristics of PCOS women cohorts in terms of weight and anthropometric 
variables, presence or absence of IR, and other metabolic disorders [19].
2. Carbohydrate disturbances and insulin resistance in PCOS
Glucose tolerance in women with PCOS was systematically investigated for 
the first time by Dunaif et al. in 1987 [20]. A number of studies involving large 
populations of PCOS women reported incidence of carbohydrate disturbances higher 
than 40% (30–35%: IGT and 8–12%: overt DM type 2) [20, 21], which is consider-
ably higher than the one observed in population studies of age-matched women. 
Overweight is a prerequisite for the development of carbohydrate disturbances, 
but Legro et al. [22] demonstrated that even lean PCOS women were exposed to a 
higher risk—31.1% had IGT and 7.5% were newly diagnosed with DM. In an Italian 
study, the incidence of carbohydrate disturbances was found to be lower—DM 2.5% 
and IGT 15.5% [23]. The Australian study of Dabadghao et al. reported incidence 
of overt DM 4% and IGT 15.6%, the latter correlating with age, family history, 
abdominal obesity, and the presence of MetS [24].
In general, the incidence of a newly diagnosed DM in targeted studies in PCOS 
women reaches 10%, the greater part of the affected women being in the third or 
fourth decade of life. Even the lower DM incidence in certain populations of PCOS 
women has proved to be significantly higher, as compared to the age-matched 
populations. For instance, in a study conducted at the University of Pittsburgh, DM 
type 2 was observed in 12.6% of PCOS women of an average age 42 years, against 
1.4% observed in the corresponding healthy population [25]. In the Netherlands, 
DM was found in 2.3% of the normal-weight PCOS women, aged 45–54, but this 
incidence was four times higher, as compared to the control population [26]. Two 
studies of ours in Bulgaria [27, 28] found DM incidence of 1.4% in a group of 142 
PCOS women and 1.1% in another group of 94 patients, which is a comparatively 
low figure. However, we must take into consideration that DM in PCOS women is 
manifested relatively later, at an age between 30 and 40, and the predominant part 
of our patients were of a younger age (average age 22 years). That is why special 
attention should be paid to the risk groups—the women with IFG and IGT (in our 
studies they were 4.9 and 7.4%, respectively) and especially those who are over-
weight or obese as well (5.8 and 6.4%, respectively) [27, 28].
The PCOS women are more predisposed to development of gestational DM as 
well [29]. On the other hand, women with gestational DM have a higher incidence 
of PCOS, diagnosed postpartum [30, 31], and this is associated with persistent car-
bohydrate disturbances occurring afterward [32], in contrast to the usual returning 
to the norm. A study involving diabetic PCOS women found that 55% of them had 
gestational DM during pregnancy [33].
Following the initial evidence of Burghen et al. concerning the presence of 
hyperinsulinemia in PCOS [34], many other investigators obtained similar results 
demonstrating that both lean and obese PCOS women are characterized by IR 
and hyperinsulinemia [35, 36]. It has been proved that PCOS women have a more 
marked IR as compared to age- and BMI-matched healthy women, the difference 
becoming greater with the increase in BMI [33–37]. The use of insulin sensitiz-
ers significantly improved the characteristic metabolic and endocrine features of 
PCOS, ovulatory function, menstrual cyclicity, and fertility [19, 38–41].
It is generally accepted that obese PCOS women are insulin-resistant. The obese 
PCOS women have higher insulin levels and/or more marked IR, as compared to 
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obese controls and normal-weight PCOS women [42]. Still debatable is the issue 
whether IR in PCOS depends on weight and/or the android redistribution of 
adipose tissue, or it is intrinsic to the disease, since there is evidence in both direc-
tions [35, 43–46]. Studies differing in design have obtained similar results, showing 
that both obese and lean PCOS women have IR and hyperinsulinemia. Some of 
these differences are due mainly to nonstandardized criteria for diagnosing both 
PCOS and IR. Family history of DM type 2 is not always taken into account. In 
addition, there are certain racial and ethnic peculiarities, which become more and 
more distinct regarding not only the individual characteristics of PCOS, but also the 
insulin sensitivity and the MetS itself [47–49].
It is important to know that irrespective of the occurrence of multiple risk 
factors, DM develops only in the presence of impaired β-cell function. In addition to 
the reduced insulin sensitivity, secretory dysfunction in pancreatic β-cells has been 
found in PCOS [50, 51]. This β-cell defect—increased fasting and reduced post-
prandial insulin secretion—results in inability of the available insulin to compen-
sate for the degree of resistance to its action. The reduced postprandial response to 
insulin in PCOS women resembles the defect typical of DM type 2 and is much more 
marked in those who have first-degree relatives with DM type 2. Weight reduction 
results in significant improvement in IR, but the β-cell defect persists [38], which 
presupposes that it may prove to be a primary abnormality in PCOS. This is sup-
ported by the fact that the β-cell is unable to compensate for the peripheral IR that 
occurs early in the course of PCOS. Thus, a reduced first phase of insulin secretion 
has been established in adolescent girls with PCOS, as well as reduced index of 
glucose disposal and increased liver glucose production [52].
As it was stated above, the PCOS women have an increased basal insulin secretion, 
although the insulin secretory response to glucose loading as a whole is inadequate, 
as compared to that of healthy women [43, 53]. On tissue level, IR develops in the 
liver, adipose tissue, and muscles of PCOS women. Hyperinsulinemia in PCOS is 
considered to be secondary to IR. The latter involves a new mechanism of marked 
defects in insulin-dependent glucose transport, with significant alterations in 
receptor dynamics [54]. Marked reduction in insulin sensitivity has been found in 
biopsy-obtained adipocytes of PCOS women, as well as a milder but also significant 
decrease in the maximum rate of insulin-stimulated glucose transport, secondary 
to the reduced expression of GLUT-4 glucose transporters [55]. Such defects are 
observed in DM type 2 and obesity, but in PCOS they are found even in the absence 
of carbohydrate disturbances, overweight, and alteration in the waist-to-hip ratio 
(WHR). Moreover, they do not correlate with sex hormone levels, which suggest 
that the impairment of insulin action is most likely primary [56].
With a view to further elucidate post-receptor defects, a reduction in insulin-
dependent receptor tyrosine autophosphorylation has been found in isolated fibro-
blasts of about 50% of PCOS women, as well as an increase in noninsulin dependent 
receptor serine phosphorylation, i.e., receptor tyrosine kinase activity is inhibited. 
A factor extrinsic to the insulin receptor, probably serine/threonine kinase, induces 
serine phosphorylation of the insulin receptor, which results in signal inhibition 
[57, 58]. This defect leads to IR in the early stages of insulin-receptor-mediated signal 
transduction. This unique PCOS characteristic distinguishes it from the other clinical 
conditions with IR [57]. The resultant hyperinsulinemia, arising as it seems upon 
triggering of puberty, may involve the system of ovarian insulin-like growth factors 
(IGFs), influence the liver production of the IGF binding protein-1(IGFBP-1), and is 
probably a pathogenetic factor in the development of the disease [59].
Serine phosphorylation seems to modulate the activity of the key regulatory 
enzyme of androgen biosynthesis—Р450с17, present in both ovarian and adrenal 
steroidogenic tissue. In this way, serine phosphorylation enhances enzymatic 
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activity and increases androgen synthesis [60]. It is interesting to note that serine 
phosphorylation of insulin receptor substrate-1 (IRS-1) is also the mechanism of 
the TNF-α-mediated IR in obesity [61]. Thus, one and the same defect—serine 
phosphorylation—is likely to result in both IR and hyperandrogenism. This is a very 
tempting hypothesis explaining the syndrome pathogenesis; unfortunately, it is 
valid for only a part (about 50%) of the population of PCOS women.
With view to establishing a defect in insulin action after binding to the recep-
tor, Book and Dunaif [62] investigated the metabolic and mitogenic effects of 
insulin and IGF-1 in a culture of skin fibroblasts from PCOS women and healthy 
controls. The authors found that in PCOS, a selective defect was present involv-
ing insulin metabolic but not mitogenic signaling pathways; a similar defect was 
found in the action of IGF-1 (this fact shows that insulin and IGF-1 stimulate 
glycogen synthetase by one and the same post-receptor pathways) [62]. Poretsky 
et al. demonstrated that the inhibition of PI-3-kinase activity did not alter insulin-
induced stimulation of progesterone production in cultures of human ovarian cells 
[63]. On the other hand, insulin-stimulated PI-3-kinase activity in skeletal muscles 
of PCOS women was damaged [64]. The results suggest that the insulin regulation 
of steroidogenesis and glucose metabolism uses different signaling pathways, the 
first one remaining functionally active and probably even overstimulated by the 
increased insulin levels in women with IR [4] (Figure 2).
The hypothesis of presence of a post-receptor defect in insulin action in PCOS is 
consistent with the results of investigations performed on a molecular level, which 
have not found structural anomalies in the insulin receptor [65–67]. What exactly 
the defect is remains to be elucidated. An evidence provided by Ek et al. [68] sug-
gests a selective impairment in the function of the protein kinase A-dependent 
hormone-sensitive enzyme lipase, which regulates the lipolytic response to catechol-
amines in visceral adipose tissue in lean PCOS women with mild IR. An abnormal 
post-receptor sensitivity to catecholamines has been observed while the antilipolytic 
sensitivity to insulin is preserved [68]. This anomaly differs from the impaired 
Figure 2. 
Role of insulin in the pathogenesis of PCOS.
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Figure 3. 
Schematic representation of the factors regulating ovarian steroidogenesis.
balance occurring in the MetS between the lipolytic β3- and the antilipolytic α2-
adrenoreceptors [69]. It is still unclear whether this unique defect found in PCOS is 
primary or secondary to other factors, such as increased serum androgen levels.
Thus, the logical question arises—if IR and hyperinsulinemia play a major patho-
genetic role in PCOS, why all women with hyperinsulinemia (e.g., with DM type 
2) are not hyperandrogenic as well? IR and reproductive disturbances are probably 
indicative of single genetic defects and IR unmasks the syndrome in genetically pre-
disposed individuals. Because of the fact that PCOS-related IR is a selective one and 
involves the metabolic but not the mitogenic and signaling pathways, we can explain 
the paradox of a persistent biological insulin action on reproductive processes on the 
background of systemic IR [70]. In general, studies have shown that predominantly 
PCOS women with both hyperandrogenism and chronic anovulation seem to be 
insulin-resistant. Women with only hyperandrogenism or a morphological finding 
of polycystic ovaries who have normal ovulation are less likely to develop IR [20, 71].
To sum up, insulin and LH act synergetically on the theca-cells of the polycystic ovary 
(hyperplasia of these cells is usually present) and activate Р450с17α1; thus, enhanc-
ing the biosynthesis of ovarian androgens and testosterone [72–75]. A further 
adverse action of hyperinsulinemia on the ovaries of PCOS women includes arrest-
ing the development of the ovarian follicle up to 5–10 mm in size and preventing 
ovulation [71, 75]. Outside the ovary, insulin can act directly as a co-gonadotropin 
enhancing LH activity by stimulating the ovarian receptors for insulin and IGF, or 
indirectly by increasing the amplitude of LH serum pulses, enhancing the sensitiv-
ity to GnRH stimulation (Figure 3).
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The possible mechanism of insulin-induced enhanced ovarian steroidogenesis 
is supported by the higher incidence of PCOS in women with DM type 1—the 
ovaries of the affected women are exposed to hyperinsulinemia resulting  
from the availability of exogenously administered insulin in the systemic  
circulation [76].
In approximately 40% of the women diagnosed with PCOS in conformity with 
the NIH (National Institute of Health) criteria, an IGT or DM type 2 developed 
as sequelae of IR in the fourth decade of life, the age and weight gain having an 
unfavorable effect on glycemic control [27, 77–80]. In addition, a study based on 
the Rotterdam diagnostic criteria, 2003 reported IR in 71.54% of the studied PCOS 
women [81].
The incidence of IR, however, differed considerably among the various pheno-
types—80.4% in the “classical” one (phenotypes А and В), 65% in the women with 
normal ovulation (phenotype С) and 38.1% in the group with normoandrogenemia 
(phenotype D). The classical phenotype and to a lesser degree the phenotype 
without ovulatory dysfunction were independently associated with IR, whereas 
in the normoandrogenic phenotype no IR was found [81]. This was confirmed by 
another study, showing that the number of women with PCOS and a HOMA-index 
>3.8 is considerably higher in the hyperandrogenic phenotypes, as compared to 
the normoandrogenic one [82]. That is why the nature and course of carbohydrate 
disturbances in women with different phenotypic presentations of PCOS require 
Confirmed Possible
Age
Obesity
Abdominal deposition of adipose tissue
Insulin resistance
β-cell dysfunction
Family history of DM type 2
Chronic anovulation
Hyperandrogenemia
Dyslipidemia (hypertriglyceridemia)
Ethnicity (certain risk populations)
Table 2. 
Risk factors for developing carbohydrate disturbances in PCOS.
Euglycemic insulin clamp technique
Minimal model—multiple determination from i.v. GTT
Sensitivity insulin infusion tests
• insulin tolerance test
• insulin suppression test
Insulin parameters in oral glucose tolerance test (oGTT)
• sum of insulin values
• area under the insulin curve
• maximal insulin/peak of insulin
Baseline insulin and derivative indexes, according to baseline blood sugar
• glucose-to-insulin ratio,
• НОМА-index (Homeostasis Model Assessment):
fasting insulin (μIU/ml) × fasting blood sugar (mmol/l) / 22.5
• QUICKI (Quantitative Insulin Sensitivity Check Index):
1/(log (fasting insulin μU/mL) + log (fasting blood sugar mg/dL))
Table 3. 
Methods for evaluation of insulin sensitivity.
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establishing a precise and timely diagnosis, as well as proper behavior by changing 
one’s lifestyle and dietary regimen, weight reduction whenever needed, with view 
to reducing the risk of developing DM and/or its complications.
The risk factors for developing carbohydrate disturbances in PCOS are presented 
in Table 2.
Having in mind the incidence of carbohydrate disturbances in the general 
population of women aged 20–44 (7.8% for IGT and 1.0% for newly diagnosed DM 
type 2) and the average prevalence of PCOS (about 5%), it can be extrapolated that 
PCOS-associated IR contributes approximately to 20% of IGT and 40% of DM  
type 2 in women of reproductive age, which gives prominence to the social 
importance of this syndrome. In the light of this evidence in 2006, the Аmerican 
Association of Clinical Endocrinologists (ААСЕ) [83] recommended screening for 
presence of DM in all PCOS women after the age of 30, irrespective of weight—
normal or overweight. Under certain risk circumstances, screening has been 
recommended before that age as well [83]. Considering the fact that DM type 2 can 
develop with age progression, the women who have had initially a negative result 
should be followed-up periodically.
The methods for evaluation of insulin sensitivity are presented in Table 3.
In the routine clinical practice a measurement of basal and during oGTT glucose 
and insulin levels is most frequently used.
3. Obesity and insulin resistance in PCOS
The association between PCOS and obesity is complex. In the USA, it was 
reported that obesity affects from 30 to 75% of PCOS women [41, 84], which 
is higher than the percentage found in Europe [85, 86]. In a systematic review 
and meta-analysis of the literature, Lim et al. concluded that in PCOS women, 
as compared to the age-matched controls, a higher incidence of overweight and 
obesity was found [87]. In addition, the carriers of the syndrome of the Caucasian 
origin were found to be more overweight than their counterparts from the Asian 
origin [87]. These results are compromised to a certain extent by the fact that 
in most of the published studies, the patients have been selected from clinical 
practices on the basis of a subjective evaluation and local diagnostic methods. In 
general, overweight women are more often referred to a specialist for searching 
PCOS. However, in independent population samples, the incidence of obesity in 
PCOS does not seem as high as the one found in clinically targeted populations 
[27, 88]. Furthermore, PCOS incidence, based on the diagnostic criteria of NIH, 
is relatively stable throughout the world, irrespectively of the variable incidence 
of obesity in different populations [89].
In one of our studies, we found obesity in 51% and overweight of 22% in an 
unselected Bulgarian population of 142 women with PCOS [27]. Obesity incidence 
in our patients was higher than 38% found in women with PCOS from the island 
of Lesbos, Greece [90], and closer to the one found in England, where around 60% 
of the studied PCOS women were obese [71]. According to many studies includ-
ing ours, PCOS women have higher ratio of central to peripheral redistribution 
of adipose tissue in comparison to controls [27, 91–94]. Obesity, of visceral type 
mainly, plays a key role in developing and maintaining the syndrome [95, 96] and 
influences significantly its severity as well as metabolic and CVD risk, since it is a 
well-known risk factor for IGT and DM type 2, IR and dyslipidemia [91, 97, 98]. In 
this respect, insulin sensitizers may exert complex positive effects on both meta-
bolic consequences and clinical manifestations of hyperandrogenism in women 
with PCOS [19, 47, 48, 83, 91] (Figure 4).
9Clinical Impact of Insulin Resistance in Women with Polycystic Ovary Syndrome
DOI: http://dx.doi.org/10.5772/intechopen.90749
Obesity may promote the onset and exacerbate other long-term sequalae of 
PCOS, including metabolic disorders, the occurrence of some types of carcinoma, 
potentiated by chronic unopposed estrogen secretion, and leads to further impair-
ing of the quality of life (QOL), low self-esteem, and worsened social adaptation, 
which may even potentiate occurrence of mental disorders. Obese PCOS women 
have a more severe clinical picture with higher incidence of IR, hyperinsulinemia, 
carbohydrate and lipid disturbances, and hyperandrogenism. Many studies, includ-
ing ours, have shown that overweight PCOS women possess a higher degree of IR in 
comparison to the lean ones [27, 91–94].
Data exist that even normal-weight carriers of the syndrome show unfavorable 
abdominal redistribution of adipose tissue and IR [99]. In a study of young normal-
weight PCOS women (mean age 15.9 ± 1.8 years, mean BMI 22.7 ± 2.3 kg/m2) 
Cree-Green et al. found reduced insulin sensitivity and mitochondrial dysfunction 
in the muscles, relative postprandial hyperinsulinemia, abnormal glucose disposal, 
and increased hepatic fat in comparison to healthy controls [100].
PCOS women frequently have decreased sex hormone-binding globulin (SHBG) 
levels, which may decrease further with obesity development [101]. In turn, SHBG 
was found to correlate positively with HDL-cholesterol and physical activity and 
negatively with obesity, central distribution of adipose tissue, triglycerides, IR 
parameters, and presence of DM type 2 [102].
In conclusion, the concomitant obesity, especially of an android type, is associ-
ated with an increase in the long-term metabolic risk in women with PCOS.
4.  Visceral adipose tissue, adipocytokines, and insulin resistance  
in PCOS
In the last decades, visceral adipose tissue is perceived as a source of biologi-
cally active substances—adipocytokines [103]. Commonly, PCOS women have 
Figure 4. 
Role of insulin sensitizers in the treatment of PCOS.
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increased amount of visceral adipose tissue and associated metabolic disorders. 
The influence of adipose tissue hormones on IR processes, carbohydrate, lipid, 
and atherogenic disorders in PCOS women is a subject of increased research 
interest [104].
4.1 Leptin
Leptin is known to act as a chief “adipostat”—it suppresses the intake of food 
and water and leads to activation of catabolic metabolic pathways related to an 
increased production of energy. It improves the peripheral (liver and musculo-
skeletal) insulin sensitivity and affects β-cell function. It has been found that 
there is a positive correlation between plasma leptin levels and the amount of adi-
pose tissue in the body. Leptin levels decrease rapidly during fasting and increase 
after food intake. Leptin is important not only for energy balance regulation and 
food intake but it also performs a function of metabolic and neuroendocrine 
hormone; participates in glucose metabolism, reproductive processes, interacts 
with the hypothalamic-pituitary-adrenal axis; influences thyroid hormone and 
growth hormone secretion; and even interferes with hematopoiesis and the 
immune system function. There are data for a strong association of circulating leptin 
and immunoreactive insulin (IRI) values and fasting plasma glucose, HOMA index, 
dyslipidemia, arterial hypertension that is independent or only partially dependent on 
obesity [103, 104].
A close relationship between IR and hyperleptinemia in PCOS women was found 
irrespective of their weight [105, 106] but the results are mostly controversial due to 
the differences in the studies designs and the lack of data on the independent effect 
of obesity, as well as the presence of various phenotype expressions of PCOS. In 
one of our studies [107], we found higher leptin levels with borderline significance 
in PCOS women in comparison to age-, weight-, waist circumference-, and WHR-
matched healthy controls. Significant correlation of leptin was found with BMI, 
waist circumference, WHR, percentage of adipose tissue, as well as with basal insu-
lin and HOMA-index in the PCOS group [107]. These findings were confirmed and 
complemented by our more recent studies of women with IR syndromes, including 
PCOS [108, 109]. Thus, leptin exhibited significantly positive correlation with 
BMI, WHR, percentage of adipose tissue, basal glucose and insulin, HOMA-index, 
total cholesterol, triglycerides, plasma atherogenic index, Castelli I, and Castelli II 
indexes. A significant negative correlation was found of leptin with Matsuda index, 
QUICKI-index, and adiponectin [108, 109].
Mohiti-Ardekani et al. [110] also found a positive correlation between free and 
total leptin levels and HOMA-index in PCOS women (r = 0.78, Р < 0.001; r = 0.84, 
Р = 0.003, respectively), as well as in healthy controls (r = 0.86, Р < 0.001; r = 0.69, 
Р < 0.001, respectively). Similar results were reported by authors from Australia 
[111], Brazil [112], Canada [113], Finland [114], Italy [115], Sweden [116], Turkey 
[117] and the USA [118, 119]. In a more recent study of PCOS women (mean age 
34.30 ± 2.08 years, mean BMI 34.84 ± 4.77 kg/m2) and normally ovulating controls 
with comparable BMI (mean age 28.10 ± 4.61 years, mean BMI 33.59 ± 1.23 kg/m2) 
Nomair et al. [120] found higher leptin concentrations in PCOS women in com-
parison to controls (P = 0.005), significant differences being found in intergroup 
comparative analysis between the insulin-resistant and non-insulin-resistant PCOS 
women as well (P = 0.044). In women with PCOS a positive correlation between 
leptin and BMI (P = 0.049) was found. Authors also consider BMI and IR the two 
chief factors associated with leptin levels [120].
Our results, as well as those from the above-mentioned studies, are indisputable 
proof for the role of leptin in the pathogenesis of IR in PCOS.
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4.2 Adiponectin
Adiponectin is a model of an anti-inflammatory adipocytokine. A negative 
correlation was found between its serum levels and the degree of obesity, IR, IGT, 
dyslipidemia, and atherosclerosis [121–123]. The increased amount of visceral 
adipose tissue results in hypoadiponectinemia due to reduced expression of adipo-
nectin genes. This leads to suppression of the insulin activity in the liver, muscles, 
and other peripheral tissues. Conversely, the high adiponectin levels are an indepen-
dent factor for an increased insulin sensitivity and reduced risk for DM type 2. On 
the basis of the effects on insulin sensitivity and its anti-inflammatory properties, 
adiponectin is perceived as an antiatherogenic factor. The decreased adiponectin 
is also combined with increased production of pro-inflammatory proteins IL-6, 
С-reactive protein (CRP). A positive correlation between the reduced levels of the 
hormone and the development of ischemic heart disease has been registered [124]. 
It was established that adiponectin production is suppressed in conditions of IR—
DM type 2 and obesity [125]. Low adiponectin levels in obesity are probably due 
to the process of “down”-regulation mediated by the increased amount of adipose 
tissue. In a study of a large population in Japan [126] and American Pima Indians 
[127], adiponectin levels were found to be in negative correlation with the indexes 
of IR even if the factors age and BMI were excluded.
Initial studies of the levels of this antiatherogenic adipocytokine in women with 
PCOS were conducted by Orio et al. [128] and Panidis et al. [129]. Orio et al. [128] 
determined serum adiponectin levels in 60 PCOS women (30 normal-weight and 
30 overweight) and in 60 age- and BMI-matched healthy women. Adiponectin 
levels were significantly lower in obese women in comparison to normal-weight 
women in the PCOS group, as well as in the control group. A significant difference 
in adiponectin levels between PCOS women and healthy women was not found, its 
levels in both groups correlated negatively with BMI and HOMA-index. The authors 
concluded that adiponectin concentrations vary depending on the quantity of the 
adipose tissue and that insulin sensitivity does not play a key role in controlling 
adiponectin levels in PCOS women [128]. Although in other IR conditions adipo-
nectin was found to be decreased, both cited studies reported that in normal-weight 
PCOS women with IR and hyperinsulinemia its levels did not differ from those in 
the controls [128, 129].
However, in PCOS women with severe IR, Sepilan et al. found that it was the 
insulin sensitivity but not the weight that was the chief determinant for adiponec-
tin levels [130]. This fact was confirmed by one of our more recent studies [131], 
which revealed higher adiponectin levels in non-insulin resistant PCOS women in 
comparison to insulin resistant ones. In addition, insulin levels and HOMA-index 
proved to be higher in the group of obese PCOS women in comparison to BMI-
matched controls while adiponectin levels were similar in both obese groups. On the 
other hand, adiponectin concentrations were significantly higher in PCOS women 
with normal BMI in comparison to those with obesity. In PCOS women a negative 
correlation between adiponectin and body weight, BMI, waist circumference, hip 
circumference, WHR, blood glucose at 60 and 120 min, IRI at 0, 60, and 120 min 
of oGTT, HOMA-index, triglycerides, triglycerides/HDL-cholesterol ratio, plasma 
atherogenic index, and leptin was found. We observed also a positive correlation 
of adiponectin with Matsuda and QUICKI indexes [109, 131]. Most probably the 
relation between adiponectin and IR is confined to the ability of this adipokine to 
stimulate glucose utilization and to reduce glucose production by the liver [71, 114]. 
The established significant correlation of adiponectin and androstenedione in 
PCOS which presupposes some interrelation between this hormone and ovarian 
steroidogenesis is very interesting and needs further elucidation [11, 131].
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It is believed that the leptin/adiponectin ratio (L/A) correlates better with the 
degree of IR in comparison to leptin and adiponectin values taken separately. L/A 
is a powerful independent predictor of CVD, its values being strongly associated 
with the intima-media thickness and correlating positively with a number of other 
anthropometric, metabolic and clinical parameters [132]. In our studies we found 
significantly higher L/A values in PCOS women with IR in comparison to those 
without IR [109, 131]. This is yet another proof that insulin resistant PCOS women 
are with a higher CVD risk.
4.3 Resistin
Resistin, described for the first time in 2001, is a protein rich in cystein, secreted 
by adipocytes, and it is suspected to carry out the relationship between obesity and 
DM. Due to its association with obesity, inflammatory process and IR, resistin is 
thought to be a potential biomarker for the MetS. Thus, the higher resistin levels 
found in patients with overt MetS in comparison to clinically healthy individuals 
support this theory [133]. However, data concerning the presence of significant 
dependencies between resistin levels and parameters of weight and insulin sensi-
tivity in basal conditions and following weight reduction are controversial. Some 
authors found significantly higher resistin levels in obese individuals in comparison 
to individuals with normal weight [134], while others, including us [135], did not 
find significant differences [136, 137].
There is controversial data in studies among PCOS women concerning resistin 
levels in terms of a lack of association with the syndrome [138, 139], or an increase 
in PCOS [140]. Thus, Panidis et al. [139] did not confirm an active role of resistin in 
the pathogenesis of PCOS. The authors compared anovulatory PCOS women (obese 
and non-obese) and healthy controls with normal weight. Resistin was significantly 
higher only in the obese PCOS women in comparison to the other two groups irre-
spectively of the differences in insulin levels and the glucose/insulin ratio. Resistin 
did not correlate with any hormonal or metabolite index in our Bulgarian popula-
tion of PCOS women with overweight [135]. Pangaribuan et al. [141] also did not 
find significant difference in serum resistin levels between PCOS women and con-
trols. Meanwhile, the authors did not find significant correlation between resistin, 
BMI and HOMA-index [141]. Similar serum resistin levels in normal-weight women 
with or without PCOS were found by Seow et al. [142]. But resistin iRNA expression 
in adipocytes was twice as high in PCOS women. Probably, the overexpression of 
the resistin gene plays a role as a local factor [142].
Olszanecka-Glinianowicz et al. [143] studied the association of adiponectin 
and resistin with the process of IR in PCOS women and controls. All study partici-
pants were divided into two subgroups—obese and normal-weight. Comparable 
serum resistin concentrations between the two subgroups of PCOS women and 
controls were observed. No correlations between the adipokines, HOMA-index 
and androgen levels were found [143]. Lewandowski et al. published similar data 
[144]. The authors did not find a correlation between adiponectin and resistin 
with the parameters of IR (basal IRI, HOMA-index, QUICKI) [144]. Yilmaz 
et al. obtained different results—higher resistin in PCOS women in comparison 
to controls, however, they observed that resistin levels remained independent of 
the degree of IR and BMI [145] which supports the data of some of the above-
mentioned studies.
The results from our studies in adipocytokines in PCOS [47, 48, 104, 107–109, 146] 
showed similar resistin levels in PCOS women and metabolically healthy obese women, 
higher resistin levels in insulin-resistant PCOS women in comparison to non-insulin 
resistant ones, lack of significant difference among the different subgroups of PCOS 
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women, divided according to BMI. Resistin correlated positively with IRI at 0 and 
120 min during oGTT, HOMA-index and negatively with Matsuda and QUICKI 
indexes [109, 146]. Wang et al. [147] registered significantly higher resistin levels in 
PCOS women (obese and normal-weight) in comparison to clinically healthy women. 
In similarity with our data, the authors reported a positive correlation of resistin with 
HOMA-index and a negative one with adiponectin [147]. Resistin in our study showed 
a positive correlation with IL-6 [109, 146]. Our data is peculiar in this aspect since it 
is considered that IL-6 is the main adipocytokine which regulates resistin levels. An 
in-vitro study showed that IL-6 production, as well as the one of other cytokines (IL-1 
and TNFα), increased resistin expression in mononuclear cells [148].
A number of studies on the relation of resistin with obesity, IR, MetS, CVD 
risk in different age populations have been conducted so far, which, though being 
controversial in some respects, lead to further clarification of the role of resistin in 
the processes of atherogenesis [149, 150]. It was found that with the increase in the 
number of MetS components, serum levels of resistin and other pro-inflammatory 
markers increase as well [150]. These and a number of other results fully support 
the hypothesis on the relation between circulating resistin levels and the degree of 
IR. Having in mind that PCOS is considered a prototype of female specific MetS in 
young age populations, the role of resistin has to be clarified.
4.4 Visfatin
Visfatin—a protein derived from adipose tissue that is considered to have anti-
diabetic properties. Visfatin is isolated in the form of a cytokine which stimulates 
β-cell precursor maturation, therefore it was called pre-β cell colony-enhancing factor 
(PBEF) [151]. Visfatin stimulates glucose utilization from the adipocytes and myo-
cytes and suppresses glucose release from liver cells, exhibiting the ability to bind to 
the insulin receptor and to activate it through inducing tyrosine phosphorylation. 
Acting as an insulin mimetic, visfatin can partially reduce IR, although it is found in 
much lower concentration in the circulation that insulin [152]. Visfatin participates 
in the process of adipocytes formation. A positive correlation between visfatin and 
the presence of obesity, increased visceral tissue, DM type 2 was found, and it was 
also elevated in patients with MetS [109, 131]. Taking in consideration these findings, 
the research interest in the changes in visfatin levels in PCOS is completely justified.
A meta-analysis [153] encompassing a study among 1341 women (695 with PCOS 
and 646 controls) showed higher visfatin levels in PCOS women without a signifi-
cant correlation between it and BMI, HOMA-index, and testosterone. The authors 
concluded that high circulating visfatin can be perceived as a specific characteristic 
of PCOS, which even presupposes a role for this adipokine as a potential diagnostic 
biomarker for PCOS [153]. Kowalska et al. [154] found higher visfatin levels and 
a reduced insulin sensitivity in both normal-weight and obese PCOS women in 
comparison to healthy controls. Visfatin correlated negatively with parameters of IR, 
this correlation being well-expressed in normal-weight PCOS women, but missing 
in obese ones. It must be noted that in some circumstances visfatin does not succeed 
in exhibiting its beneficial effects on carbohydrate metabolism [154]. A hypothesis 
that the increase in serum visfatin levels is a secondary process aiming to prevent IR 
exists. On the other hand, insulin possesses the property to inhibit visfatin expres-
sion from the adipocytes so that the observed interrelationship could be explained as 
an inability of insulin to inhibit visfatin production in an already developed insensi-
tivity to its action [155]. In this context, in the study of Kowalska et al. a positive cor-
relation of visfatin with total testosterone and free androgen index (FAI) in the lean 
PCOS women was established [154]. The study of Tan et al. [156] also confirmed 
higher visfatin levels in PCOS women in comparison to age- and weight-matched 
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healthy women. The researchers found a stimulated process of expression of visfatin 
mRNA and of the protein precursor of visfatin both in subcutaneous and visceral 
adipose tissue in PCOS women. Plasma visfatin levels were in a positive correlation 
with basal IRI (Р < 0.01), HOMA-index (Р < 0.01), testosterone (Р = 0.03), and 
estradiol (Р = 0.046). After performing a multiple regression analysis, the research-
ers found that the HOMA-index was the only predictive factor for visfatin levels. In 
contrast to plasma visfatin levels, the expressed visfatin mRNA in subcutaneous and 
visceral adipose tissue correlated positively with BMI and WHR [156].
In our Bulgarian studies [109, 131], we found higher serum visfatin levels 
in insulin-resistant PCOS women in comparison to non-insulin resistant ones. 
Visfatin levels in the PCOS women with obesity/overweight and in the BMI-
matched metabolically healthy controls did not differ significantly. In our PCOS 
women, a negative correlation of visfatin with HDL-cholesterol and Matsuda index 
was found as well as a positive one with diastolic arterial pressure [109, 131]. In 
similarity to our results, Kowalska et al. reported a negative correlation between 
visfatin and HDL-cholesterol (r = −0.27, Р = 0.004) [154]. Such negative correla-
tion (r = −0.349, Р = 0.013) was confirmed also by El-Said et al. [157] in insulin 
resistant PCOS women. In addition, the authors reported a positive correlation of 
visfatin with BMI, waist circumference, HOMA-index, FAI and a negative one with 
LH, total testosterone and sex hormone-binding globulin (SHBG). In this study, 
as well, visfatin was significantly higher in the PCOS women in comparison to the 
healthy women (72.94 ± 33.3 vs 54.69 ± 31.5 ng/mL, Р = 0.039) [157]. In contrast to 
our results and the ones mentioned so far, Gen et al. reported a positive correlation 
between visfatin and HDL-cholesterol in normal-weight PCOS women [158].
It appears that there is controversy with respect to the relation of visfatin with 
insulin sensitivity indexes in women with IR and namely with PCOS and MetS. The 
main action of visfatin is intended at prevention of IR development as it was already 
pointed out, and this can explain its increase in PCOS women. The negative correla-
tion of visfatin with IRI and HOMA-index and respectively the positive one with 
atherogenic indexes QUICKI and Matsuda in women with overt MetS registered in 
our studies is in support of this suggestion. Visfatin secretion control is a subject 
of increased research interest that arises much debate. Up till now, the conducted 
clinical studies comprising insulin resistant individuals with obesity and MetS, 
exhibit controversial results. The changes in this adipocytokine in PCOS women 
with different phenotypes are still to be clarified in targeted studies.
4.5 Tumor necrosis factor α (TNF-α) and Interleukin-6 (IL-6)
Adipose tissue is an important source of factors of low-grade inflammation not 
only due to the production of various cytokines by the adipocytes themselves, but 
also because of tissue infiltration with pro-inflammatory macrophages. The adipose 
tissue macrophages are responsible for the production of almost the entire amount 
of TNF-α and a significant portion of IL-6 [159].
TNF-α is a cytokine, which interferes with the regulation of the amount of 
adipose tissue (inhibits the conversion of young immature fat cells into mature 
ones), the insulin action (disrupts the insulin receptor signal in peripheral cells) 
that causes post-receptor defect with subsequent development of IR [160]. The data 
regarding its relationship with IR are not consistent—some authors do not find any 
[161], but according to others insulin sensitivity is changing in parallel with the 
change in this cytokine levels [162, 163]. We also did not find a significant correla-
tion of TNF-α and some parameters of IR in patients with various obesity morphot-
ypes [135]. Basically, in our study, TNF-α levels were very similar in normal-weight 
women and in obese women, which corresponds to the data of Pincelli et al. [164]. 
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It seems that the TNF-α levels, which we measure in the circulation, cannot reflect 
the degree of IR in obesity. It should be taken into account that this cytokine can 
have predominantly autocrine or paracrine action and can induce IR at a tissue 
level, since its concentrations in situ, at the level of adipose tissue, are much higher 
in comparison to the circulatory ones [165].
Elevated levels of TNF-α have been observed in PCOS women, which correlated 
positively with BMI and negatively with insulin sensitivity [166]. Gonzalez et al. 
[167] found elevated levels of TNF-α in normal-weight PCOS women as compared 
to controls. However, in all obese women in this study, despite the absence/presence 
of PCOS, TNF-α levels were similar. Direct correlation of TNF-α was detected with 
BMI, but with insulin such a correlation was found only in the healthy women. 
Apparently, factors other than obesity were the cause of TNF-α increase in normal-
weight PCOS women. On the other hand, this cytokine did not correlate with 
testosterone, LH, and DHEA-S in the PCOS women [167].
We found significantly higher TNF-α concentrations in PCOS women compared 
to BMI-matched controls [109, 131]. In our studies, we did not establish a significant 
difference when comparing serum levels of TNF-α between insulin-resistant and 
non-insulin-resistant PCOS women. Higher levels of TNF-α were registered in 
obese PCOS women as compared to overweight PCOS women, but not to normal 
weight PCOS women. No correlations between TNF-α and the parameters of IR 
were established in the PCOS women [109, 131]. Contrary to our results are those of 
Soares et al., who did not detect a significant difference in the TNF-α levels between 
PCOS women and BMI-matched controls [168].
Data are controversial regarding the role of IL-6 in the development of IR. In 
general, it is considered that circulating levels of IL-6 are elevated in patients with 
obesity and IR. It is assumed, that persistent high levels of IL-6 in chronic inflamma-
tory conditions (obesity and DM type 2) can cause disturbances in insulin sensitivity, 
while only periodically elevated IL-6 levels are associated with normal carbohydrate 
homeostasis [162, 169]. Lin et al. suggested that IL-6 may serve as an early chronic low-
grade-inflammation marker in PCOS [170]. This hypothesis, also described by other 
authors [171, 172], launches the idea of an association of PCOS with increased CVD 
risk, and the strategies affecting the chronic low-grade inflammatory conditions, can 
be useful for coping with PCOS and related metabolic and atherogenic disorders [173].
Mohlig et al. [174] studied IL-6 and CRP in PCOS women and in age-matched 
controls, analyzing the influence of C-174G-IL-6 gene polymorphism on the 
IL-6 and androgens levels, and on the degree of obesity. The authors did not find 
elevated CRP and IL-6 levels in PCOS women (both lean and obese) compared to 
the controls. In PCOS women the anthropometric variables (BMI, WHR, amount 
of adipose tissue) and the parameters of IR, but not the markers of hyperandro-
genic condition, showed significant correlation with IL-6 and CRP. In addition, a 
6-month metformin treatment resulted in a significant decrease in the body weight, 
the amount of adipose tissue and total testosterone levels, but did not affect the lev-
els of IL-6 and CRP. Using multivariate linear regression analysis, it was established 
that in PCOS women BMI but not HOMA-index constituted a dominant factor 
explaining 18% and 24% of the variations in IL-6 and CRP levels, respectively [174].
This fact was also confirmed by another study conducted in pre-menopausal 
women [175]. In the study of Mohlig et al. [174], no link between the C-genotype 
and the IL-6 and BMI levels was found. However, the heterogeneous GC genotype 
was associated with lower levels of androstenedione [174]. The C-174G polymor-
phisms of the IL-6 gene promoter could be expected to modify its activity in certain 
in vitro conditions [176]. In some studies, C-174G polymorphism was associated 
with higher levels of IL-6, with more pronounced IR, with a higher degree of 
obesity and with hyperandrogenism [177, 178].
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Our studies [107–109, 131] showed similar levels of IL-6 between the groups 
of PCOS women—insulin-resistant vs non-insulin-resistant; normal weight vs 
overweight and obese. We did not establish a significant difference in IL-6 between 
PCOS women and controls. Our data are in conformity with those of Villuendas 
et al. in women with ovarian hyperandrogenism [179], but are in confliction with 
the results of another study of Kelly et al. in PCOS women [180].
In a study of Tarkun et al. [181] in PCOS women and age- and weight-matched 
healthy women, a comparative analysis of TNF-α and IL-6 was made, with an 
assessment of their role in IR pathogenesis. Higher concentrations of TNF-α and 
IL-6 were found in PCOS women compared to controls. A positive correlation was 
observed between TNF-α and BMI, waist circumference, triglycerides, basal insulin 
and HOMA-index (P < 0.001). IL-6 correlated positively with basal glucose and 
degree of IR (P < 0.05). The authors concluded that TNF-α and IL-6 have a patho-
genetic role in the development of IR in PCOS [181].
In another study consisting of obese PCOS women, weight-matched healthy 
women and normal weight controls Vgontzas et al. [182] determined basal cyto-
kine concentrations and conducted an 8-h nocturnal polysomnography searching 
for obstructive sleep apnea syndrome. Higher IL-6 plasma concentrations were 
observed in PCOS women as compared to obese and normal-weight controls 
(4.75 ± 0.5; 3.65 ± 0.4; 1.84 ± 0.3 pg/mL, respectively, P < 0.01). TNF-α levels were 
somewhat higher in the obese PCOS and control women compared to the normal-
weight women, but the differences did not reach statistical significance (4.05 ± 0.3; 
3.79 ± 0.2; 3.14 ± 0.2 pg/mL, respectively, P = 0.103). IL-6 and TNFα correlated 
positively with BMI (P < 0.01) in the obese healthy women, but not in the obese 
PCOS women. In addition, a stronger correlation of IL-6 and TNF-α levels with 
IR indexes (HOMA and QUICKI) was established in the PCOS women than in the 
obese controls. The authors came to the conclusion that IL-6 may be elevated in 
PCOS women, irrespectively of obesity and presence of obstructive sleep apnea, 
and may have a role in the process of IR in this syndrome [182].
Grimaldi Barcellos et al. [183] investigated the impact of PCOS and obesity 
on the levels of TNFα, IL-6 and CRP in young PCOS women and age- and BMI-
matched women with a normal menstrual cycle without CVD risk factors (DM, 
dyslipidemia, arterial hypertension). The authors did not establish a significant 
difference in the levels of TNF-α, IL-6 and CRP between the PCOS women and the 
controls (2.1 vs 1.9 pg/mL, P = 0.397; 3.8 vs 5.7 pg/mL, P = 0.805, and 0.9 vs 0.5 ng/
mL, P = 0.361). The TNF-α levels were similar between obese and normal-weight 
women. IL-6 and CRP were significantly higher in women with overweight/obesity 
than in normal-weight women (8.7 vs 2.0 pg/mL, P < 0.001, and 1.4 vs 0.2 ng/mL, 
P < 0.001). The authors concluded that obesity, but not PCOS itself, affects the 
levels of circulating markers of a chronic low-grade inflammation in young carriers 
of the syndrome without major CVD risk factors [183].
The pathogenesis of an inflammatory process development in MetS, and in partic-
ular in PCOS, has not yet been fully clarified. In scientific terms, the most logical and 
most widespread is the explanation that the higher amount of adipose tissue in case 
of obesity leads to increased excretion of IL-6 and TNF-α in the circulation, which 
in turn causes increased production of CRP by the liver. There is another hypothesis 
highlighting IR as the primary cause of the higher production of cytokines [184].
5. Conclusion
Women with PCOS, combining IR and hyperandrogenism are carriers of an 
unfavorable cardiovascular risk profile. However, data concerning the long-term 
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risk of cardiovascular morbidity and mortality are scarce, controversial and this 
issue has not yet been addressed appropriately in targeted large prospective studies. 
However, since there is compelling evidence of the presence of MetS components 
and early stages of atherosclerotic processes in young PCOS women that are still 
reversible, it is essential that they must be diagnosed on the basis of the current 
knowledge in order to administer adequate complex treatment to prevent late 
consequences of IR.
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